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Abstract: The extent to which pulmonary arterial hypertension (PAH) experts share common practice pat-
terns that are in alignment with published expert consensus recommendations is unknown. Our objective was
to characterize the clinical management strategies used by an international cohort of self-identiﬁed PAH ex-
perts. A 32-item questionnaire composed mainly of rank order or Likert scale questions was distributed via the
Internet (August 5, 2013, through January 20, 2014) to four international pulmonary vascular disease or-
ganizations. The survey respondents (N ¼ 105) were ﬁeld experts reporting 11.6   8.7 years of PAH experience.
Likert scale responses (1 ¼ disagree, 7 ¼ agree) were 3.0–5.0, indicating a disparity in opinions, for 78% of
questions. Respondent (dis)agreement scores were 4.4   2.2 for use of expert recommendations to deter-
mine catheterization timing in PAH. For PAH patients without cardiogenic shock or known vasoreactivity
status, the most and least preferred ﬁrst-line therapies (1 ¼ most preferred, 5 ¼ least preferred) were phospho-
diesterasetype5inhibitors (PDE-Vi)andsubcutaneous prostacyclin analogues, respectively(1.4   0.8 vs.4.0 
1.1; P < 0.05). Compared with US-practicing clinicians (N ¼ 46), non-US-practicing clinicians (N ¼ 57)favored
collaboration between cardiology and pulmonary medicine for clinical decision making (1 ¼ disagree, 7 ¼
agree; 3.1   2.2 vs. 4.8   2.2; P < 0.0001) and PDE-Vi (6.5% vs. 22.4%) as ﬁrst-line therapy for PAH patients
with cardiogenic shock but were less likely to perform vasoreactivity testing in patients with lung disease–
induced pulmonary hypertension (4.3   2.1 vs. 2.2   1.6; P < 0.0001). In conclusion, practice patterns among
PAH experts diverge from consensus recommendations and differ by practice location, suggesting that oppor-
tunity may exist to improve care quality for this highly morbid cardiopulmonary disease.
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INTRODUCTION
Adherence to standardized care is an established contrib-
utor to improved outcome in various cardiovascular and
respiratory diseases, including coronary artery disease, ge-
netic cardiomyopathies, and asthma, among others.
1-3 The
development of evidence-based expert consensus guide-
lines, which now exist across virtually all clinical scenarios
in cardiopulmonary medicine,
4 deﬁne disease-speciﬁc met-
rics for diagnosis, treatment, and long-term patient manage-
ment. Consensus guideline recommendations, in turn, have
evolved as a premium strategy by which to improve quality
of care and clinical outcomes for patients with cardiopul-
monarydisease.
5
Pulmonary arterial hypertension (PAH) is a severe car-
diopulmonary disease associated with substantial morbidity
and premature longevity.
6,7 A range of pulmonary circulation–
speciﬁc pharmacotherapeutic and surgical strategies has
emerged recently to improve functional capacity, quality of
life, and survival in PAH.
8,9 Despite these advances, there
is substantial underdiagnosis and inappropriate treatment
of PAH in clinical practice.
10,11 To address these issues, an
international effort was undertaken in 2009 to establish the
ﬁrst expert consensus documents in the contemporary era
for the diagnosis, treatment, and management of PAH pa-
tients.
12-14 Since then, however, there have been numerous
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ment strategies for patients with PAH.
15-17 Practice patterns
in PAH are reported to differ by institution,
18 by era of
practitioners,
19 and even by geographic region.
20,21
Taken together, these ﬁndings suggest that penetration
of expert consensus recommendations into clinical practice
in PAH may as yet be unrealized. However, there are few
empirical data with which to address this concern. To ﬁll
this gap in our present understanding of treatment patterns
in PAH and to identify areas in which a signiﬁcant lack of
consensus remains among experts regarding care, a survey
containing questions relevant to assessment, diagnosis, and
treatment of PAH was distributed to an international co-
hort of PAH and pulmonary vascular disease specialists.
METHODS
This survey study was approved by the investigational re-
view board for patient safety and privacy at Brigham and
Women’s Hospital and complies with the Declaration of
Helsinki. Written consent was implied by completion of
the questionnaire.
Survey content
The complete survey is available at http://pvri.info/content
/pulmonary-hypertension-clinician-survey. In general, sur-
veys consisted of (1) a cover letter outlining the purpose of
the survey and soliciting participation from self-identiﬁed
PAH experts, (2) a general information respondent form,
and (3) 28 multiple choice, rank order, or 7-point Likert
scale questions (1 ¼ disagree, 7 ¼ agree; Table 1).
22,23 The
topics relevant to PAH clinical practice under investigation
were practice patterns related to hemodynamic and pulmo-
nary vasoreactivity testing, selection and implementation of
PAH-speciﬁc drug therapies, and clinical management of
PAH patients. In some cases, questions involving clinical
practice preferences for pulmonary vascular diseases other
than PAH were included, particularly with respect to pa-
tients with pulmonary hypertension due to lung disease
(i.e., World Health Organization [WHO] group 3 pulmo-
nary hypertension). The rationale for including questions
addressing practice proﬁle differences in these patients
was based on overlap in pathophenotype
10 and diagnostic
approach
12 reported by some for WHO group 3 and PAH
patients and on ongoing debate within the larger pulmo-
nary vascular disease community regarding optimal treat-
ment of WHO group 3 pulmonaryhypertension. An expert
in the ﬁeld of survey science performed survey validation,
and a pilot trial of the survey was offered to selected mem-
bers of the Pulmonary Vascular Research Institute (PVRI)
prior to initiation of the study.
Survey distribution
Members of the PVRI, the European Respiratory Society,
the Pulmonary Hypertension Association, and the Ameri-
can Thoracic Society received an e-mail announcing the
survey. The message contained an electronic link to the
survey on the PVRI website, which was available for com-
pletion between August 5, 2013, and January 20, 2014.
These organizations were selected for participation in this
study owing to a strong track record of PAH and pulmo-
nary vascular disease publications authored by association
members.
12,24-26 Survey question responses were anony-
mously and automatically stored in the PVRI database, and
data were transposed to Microsoft Excel prior to analysis.
Statistical analysis
All statistical analyses were performed using Origin
(ver. 9.1; Northampton, MA). Categorical variables are re-
ported as frequencies; unless otherwise indicated, continu-
ous data are expressed as mean   SD (range). The un-
paired Student t test was used to compare two independent
groups. Comparisons between multiple groups were made
using one-way analysis of variance (ANOVA).
RESULTS
Study population
A total of 105 anonymous individual surveys were com-
pleted and submitted during the study period (80 men;
mean age, 47.3 years; age range, 29–68 years; Table 2). Sur-
vey respondents were from 25 countries and 6 continents
(Fig. 1A) and were trained principally in pulmonary med-
icine (N ¼ 63) and cardiology (N ¼ 29), although a total of
6 clinical specialties and nursing were represented (Fig. 1B).
Participants reported 11.6   8.7 years of PAH clinical
practice, with 43.1% of all clinical effort devoted to PAH
patients. Clinicians’ PAH patient panels were generated
by local and nonlocal referrals for 91.4% and 80.0% of
respondents, respectively, and a majority (57.4%) reported
employment at an institution with an active heart/lung
transplant program. All survey respondents reported partic-
ipation in PAH research, which involved basic science
(48.5%), preclinical studies (30.4%), and/or clinical trials
(80.9%). Involvement in ≥2 areas of research was reported
by 38 (36.1%) survey participants, and 20 (19.0%) respon-
dents reported participation in all research areas. Among
4 commonly available clinical practice resources, study
participants rank ordered expert consensus recommen-
dations as the most inﬂuential on clinical practice (1.6  
0.9 on a scale of 1 [most useful] to 5 [least useful]), fol-
lowed by international scientiﬁc sessions (1.7   0.9), per-
s o n a lc l i n i c a le x p e r i e n c e( 3 . 5  1.3), and information provided
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parison across groups).
Invasive cardiopulmonary hemodynamic assessment
and pulmonary vasoreactivity testing
Despite the importance of invasive cardiopulmonary he-
modynamic assessment and vasoreactivity testing on di-
agnosis and prognosis in PAH,
27 the application of right
heart catheterization (RHC), left heart catheterization (LHC),
and/or confrontational pulmonary vasodilator testing in clin-
ical practice is controversial.
28 Thus, the survey consisted of
a series of questions relevant t oR H C( T a b l e3 )a n dL H C(T a -
ble 4) in PAH. Participants reported 4.4   2.2 (1–7) on a 7-
point Likert scale (1 ¼ disagree, 7 ¼ agree) in response to
a statement assessing (dis)agreement with expert consen-
sus recommendations as a key resource for determining
the timing of RHC for diagnosis/prognosis of PAH. Sim-
ilar trends were reported for the role of invasive cardiopul-
monary hemodynamic assessment in PAH patient man-
agement beyond diagnosis: (dis)agreement scores for RHC
as a routine method to assess treatment efﬁcacy or to eval-
uate further clinical deterioration were 4.1   2.0 (1–7) and
4.4   2.1 (1–7), respectively. Increased parity was reported
for the role of repeat vasoreactivity testing as a component
of routine clinical care in PAH (2.9   2.0 [1–7]), and agree-
ment was reported in favor of echocardiography for the rou-
tine monitoring of right ventricular function in clinically
stable patients (6.1   1.4 [1–7]).
(Dis)agreement scores for pulmonary vasoreactivity test-
ing in patients with suspected WHO group 3 pulmonary
hypertension (i.e., lung disease–induced pulmonary hyper-
tension), for which evidence-based guidelines do not exist,
were 3.1   2.1 (1–7). However, it is worthwhile to note
that differences with respect to this issue were observed
Table 1. Survey outline
Section focus Items (N) Question types Topics addressed
PAH diagnosis 10 Likert: 5
Multiple choice: 5
Catheterization and vasoreactivity assessments for PAH diagnosis:
• Timing
• Indications
•M e t h o d s
PAH drug therapy 14 Likert: 6
Rank order: 7
Multiple choice: 1
Drug therapy selection/preference:
• By clinical scenario (PAH)
• By clinical scenario (RV failure)
• Barriers to drug selection
Health insurance type in clinical practice:
• National health plan vs.
• Work insurance program vs.
• Private health insurance vs.
• Patient self-pay
PAH clinical assessment 8 Likert: 7
Rank order: 1
Clinical follow-up:
• Ambulatory monitoring
• Laboratory assessment
• Imaging/catheterization
Resources for clinical decision making:
• Academic resources
• Clinical collaborations with consultants
Note: PAH: pulmonary arterial hypertension; RV: right ventricle.
Table 2. Survey cohort characteristics
Proﬁle of respondents (N = 105) Result
Men, N 80
Age, mean (range), years 47.3 (29–68)
PAH practice experience, years 11.6   8.7
Total clinical hours/week 36.7   17.3
Total PAH clinical hours/week 15.8   12.1
Participants in PAH research, % 100
Research foci/focus, %
Basic science 48.5
Preclinical studies 30.4
Clinical trials 80.9
Note: Data are mean   SD, unless otherwise indicated. PAH:
pulmonary arterial hypertension.
Pulmonary Circulation Volume 4 Number 3 September 2014 | 443according to the mode of healthcare reported for PAH
patients by survey respondents. Compared with survey
participants for whom health insurance of patients was
reported to be mainly through a national health plan (N ¼
62), those survey participants for whom health insurance
of patients was reported to be mainly through private health
insurance (N ¼ 17) tended to be more agreeable with vaso-
reactivity testing for WHO group 3 patients (2.8   2.0 vs.
4.4   2.1; P < 0.01; Fig. 2).
PAH treatment
A key determination of the 2009 expert consensus
guidelines in PAH was establishing the role of treatment
with calcium channel antagonists as the primary phar-
Figure 1. Geographic distribution and clinical training expertise of survey respondents. Pulmonary vascular disease experts (N ¼ 105)
completed an Internet-based survey to characterize differences in pulmonary arterial hypertension clinical practice patterns. A,
Respondents were from 25 countries on 6 continents. B, The survey cohort included healthcare professionals trained in 7 medical
specialties and nursing.
Table 3. Responses to questions involving the relevance of cardiac catheterization and pulmonary vasoreactivity testing to the
diagnosis/management of pulmonary arterial hypertension
Survey question
Response (N ¼ 105),
mean ± SD (range)
A key guideline for determining the timing of invasive hemodynamic assessment for patients with
pulmonary arterial hypertension (PAH) in your practice is the expert consensus guideline statement
on the topic published in 2009
12 4.4   2.2 (1–7)
It is reasonable to perform pulmonary vasoreactivity testing as part of the clinical evaluation for patients
with suspected chronic lung disease–induced pulmonary hypertension (i.e., World Health Organization
[WHO] group 3 pulmonary hypertension) 3.1   2.1 (1–7)
A substantial decrease in pulmonary hypertension severity on pulmonary vasoreactivity testing inﬂuences
your choice of ﬁrst-line pulmonary vasodilator therapy in patients requiring treatment of symptomatic PAH 5.6   1.7 (1–7)
Rightheartcatheterization isa routine strategy bywhich to monitor(i.e., follow-up)the treatmentresponsiveness
ofPAHpatientstopulmonaryvasodilatortherapy 4.1   2.0 (1–7)
Among patients initiatedon pulmonarycirculation–speciﬁctherapyfollowinginvasivehemodynamic assessment,
arepeat right heart catheterization is performed in your practice in patients with clinical deterioration only 4.3   2.1 (1–7)
Note: Answers are reported on the basis of a 7-point Likert scale (1 ¼ disagree, 7 ¼ agree).
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soreactivity in response to acute pulmonary vasodilator
challenge in the absence of cardiogenic shock.
29 In re-
sponse to a survey question addressing (dis)agreement with
this recommendation (1 ¼ disagree, 7 ¼ agree), results were
4.7   2.3 (1–7). In turn, among PAH patients with unknown
vasoreactivity status without cardiogenic shock, (dis)agree-
ment with calcium channel antagonist therapy as ﬁrst-line
treatment was (1 ¼ disagree, 7 ¼ agree)1.6   1.5 (1–7). Fur-
thermore, rank order analysis of ﬁrst-line agents under
these clinical conditions presented in order of most to least
preferred was phosphodiesterase type 5 inhibitor (PDE-Vi),
nonselective endothelin receptor antagonist (ERA), selective
endothelin type A receptor antagonist (ETARA), inhaled
prostacyclin analogue (PGI2), parenteral PGI2,a n ds u b c u t a -
neous PGI2 (1.4   0.8 vs. 2.3   1.0 vs. 2.5   1.1 vs. 3.4   1.2
vs. 3.6   1.3 vs. 4.0   1.1; N ¼ 105; P < 0.05 by ANOVA;
Fig. 3A). Interestingly, preference for PDE-Vi as ﬁrst-line
therapy in WHO group 3 pulmonary hypertension was less
well established, with respondents reporting a (dis)agree-
ment score of 4.0   2.1 (1–7). With respect to strategies
involving initiation of dual pulmonary vasodilator therapy, a
tendency toward agreement with maximizing the drug dose
of a single pulmonary hypertension–speciﬁc therapy prior to
initiation of an additional pulmonary hypertension-speciﬁc
therapy was observed (4.9   1.6 [1–7]).
In concert with expert consensus recommendations, par-
enteral PGI2 was identiﬁed by a majority (69.5%) of survey
respondents as the preferred ﬁrst-line treatment of PAH
patients with cardiogenic shock, although PDE-Vi and ERA
were selected by 16.5% and 10.5% of respondents, respec-
tively (Fig. 3B). Greater disparity was observed for the pre-
ferred inotropic agent to support cardiac output in patients
with right ventricular dysfunction due to PAH (Fig. 4).
Five common barriers to the implementation of pre-
ferred therapy in PAH across the study cohort were rank-
ordered by survey participants (N ¼ 105; 1 ¼ most com-
mon, 5 ¼ least common; Table 5). Overall, patients’ social
circumstances preventing drug compliance was reported
as the strongest factor to limit optimal treatment selection,
while access to drug therapy was least likely to inﬂuence
drugselection(2.3 0.1vs.3.6 0.1;P<0.001).
Ambulatory care strategies
Periodically measuring biochemical evidence of heart
failure and functional capacity is reported as an accept-
able strategy by which to monitor the clinical trajectory of
PAH in the ambulatory setting,
30 although the extent to
which this is applied in clinical practice is unknown. Re-
sponses indicating (dis)agreement with the routine mea-
surement of 6-minute walk distance or plasma brain na-
Table 4. Role of left heart catheterization (LHC) in the
diagnosis of pulmonary arterial hypertension
LHC survey question
Response,
N (%)
LHC is not a part of the cardiopulmonary
hemodynamic assessment in my practice 58 (55.2)
LHC is always performed unless contraindicated 30 (28.5)
LHC is performed only if the transpulmonary
gradient is ≥10 mmHg 6 (5.7)
LHC is performed only if the pulmonary capillary
wedge pressure is <15 mmHg 5 (4.7)
Note: Results are responses reported in answer to the follow-
ing question: “Which (one) of the following best characterizes
the circumstances under which LHC is performed at the time of
right heart catheterization in your practice (choose 1)?”
Figure 2. Patients’ economic healthcare status inﬂuences the
opinion of pulmonary arterial hypertension (PAH) experts on
pulmonary vasoreactivity testing in pulmonary hypertension due
to lung disease. An international cohort of pulmonary vascular
disease experts (N ¼ 105) completed an Internet-based survey
soliciting a response of (dis)agreement to the following statement:
“It is reasonable to perform pulmonary vasoreactivity testing as
part of the clinical evaluation for patients with suspected chronic
lungdisease–inducedpulmonaryhypertension (i.e., World Health
Organization [WHO] group 3 pulmonary hypertension).” Results
are presented by primary health insurance coverage (national
healthcare system vs. private healthcare insurance) of PAH pa-
tients in the practice of each respondent, as reported in the survey
byrespondents.Dataareexpressedasmean  SD.
Pulmonary Circulation Volume 4 Number 3 September 2014 | 445triuretic peptide concentration were 5.0   1.7 and 4.7   1.6,
respectively. Along these lines, an evolving trend in the
management of patients with complex pulmonary vascular
disease is through a multidisciplinary effort between pulmo-
nary medicine and cardiology, among other disciplines.
31
Whereas (dis)agreement scores were 4.2   2.2 that key
decisions for the management of PAH patients are achieved
through a consensus decision between a pulmonary med-
icine and a cardiology expert, we observed a signiﬁcant dif-
ference with respect to this issue by geographic location.
Compared with US-practicing clinicians (N ¼ 46), a greater
tendency to report joint pulmonary-cardiology collabora-
tions in PAH management was observed among non-US-
practicing clinicians (N ¼ 59; 3.1   2.2 vs. 4.8   2.2; P <
0.0001;Fig. 5).
Regional differences in care and treatment patterns
Owing to our observation that use of joint pulmonary-
cardiology collaborations in PAH differs between US and
non-US experts, we next explored the effect of these regional
differences on diagnostic and treatment strategies in PAH
and other pulmonary vascular diseases. We observed no sig-
niﬁcant difference between US-practicing (N¼ 46) andnon-
US-practicing (N ¼ 59) clinicians with respect to (dis)agree-
ment scores (1 ¼ disagree, 7 ¼ agree) for use of 6-minute
walk distance (4.7   1.7 vs. 5.2   1.8; P =0 . 1 1 ) ,p l a s m aB -
type natriuretic peptide (4.8   1.8 vs. 4.6   1.3; P ¼ 0.38),
and echocardiography (6.0   1.5 vs. 6.1   1.2; P ¼ 0.64) to
monitor the clinical progress of PAH patients in the ambu-
Figure 3. Pulmonary vasodilator therapy preference in pulmonary arterial hypertension (PAH). A, An international cohort of
pulmonary vascular disease experts (N ¼ 105) ranked ﬁrst-line pulmonary vasodilator therapy by preference for the treatment of
PAH patients without cardiogenic shock in whom the response to vasoreactivity testing was not established. 1 ¼ most preferred,
5 ¼ least preferred. B, Experts identiﬁed the most preferred drug therapy for the ﬁrst-line treatment of PAH patients with cardiogenic
shock. PDE-Vi: phosphodiesterase type 5 inhibitor; ERA: endothelin receptor antagonist; ETARA: selective endothelin type A recep-
tor antagonist; PGI2: prostacyclin analogue.
Figure 4. Inotropic therapy preference for patients with right
ventricular failure due to pulmonary arterial hypertension (PAH).
An international cohort of pulmonary vascular disease experts
(N ¼ 105) completed an Internet-based survey soliciting the se-
lection of one of 6 provided answer options to the following ques-
tion: “In patients with right ventricular failure secondary to PAH,
which inotrope do you prefer to maintain sufﬁcient cardiac out-
put?” Data are expressed as percentage of responses.
446 | Pulmonary hypertension clinical care quality Ryan et al.latory setting. Compared with non-US-practicing clinicians,
US-practicing clinicians reported a similar tendency to uti-
lize invasive cardiopulmonary hemodynamic assessment
as a routine test performed during follow-up of PAH pa-
tients prescribed vasodilator therapy (1 ¼ disagree, 7 ¼
agree; 4.1   2.0 vs. 4.2   2.0; P ¼ 0.91); however, a signiﬁ-
cant difference was observed between groups with respect to
performing vasoreactivity testing in the diagnostic evalua-
tion of patients with WHOgroup 3pulmonary hypertension
(2.2  1.6vs.4.3 2.1;P<0.0001;Fig.6A).
Rank order analysis of 6 potential ﬁrst-line agents for
the treatment of PAH patients without cardiogenic shock
in the absence of known pulmonary vasoreactivity status
revealed that PDE-Vi therapy is favored similarly by non-
US-practicing and US-practicing clinicians (1 ¼ most
preferred, 5 ¼ least preferred; 1.4   0.9 vs. 1.5   0.7; P ¼
0.71). However, whereas US-practicing physicians were
more likely than non-US-practicing clinicians to favor
ﬁrst-line therapy in this clinical situation with subcu-
taneous PGI2 (3.7   1.3 vs. 4.3   0.9; P < 0.01) and
parenteral PGI2 (3.2   1.3 vs. 3.8   1.2; P <0 . 0 2 ) ,t h e
opposite trend was observed for ERA use (2.7   0.9 vs.
2.0   1.0; P < 0.002). The percentage of respondents identi-
fying each of 6 therapies as preferred for the ﬁrst-line treat-
ment of symptomatic PAH patients with cardiogenic shock
according to practice location is provided in Figure 6B,
which illustrates differences between non-US-practicing and
US-practicing clinicians for the selection of PGI2 (56.9% vs.
86.9%), PDE-Vi (22.4% vs. 6.5%), and inhaled PGI2 (15.5%
vs. 2.1%).
DISCUSSION
This is the largest empirical report to date to character-
ize the opinions and clinical practice patterns of PAH
experts, which was deﬁned in this study as substantial
PAH experience, academic focus, and international dis-
tribution of practice locations reported by the survey re-
spondents. Our ﬁndings demonstrate important disparity
among study participants in each of the measured facets
of relevance to PAH clinically, including strategies for
diagnosis, pharmacotherapy selection, and ambulatory pa-
tient management. Although participants identiﬁed expert
consensus recommendations as the most valued resource
for clinical decision making in PAH, results from this sur-
vey indicate that practice patterns diverge from these
recommendations in several areas, particularly with re-
spect to indications for RHC/pulmonary vasoreactivity
testing as well as evidence-based algorithms for PAH ther-
apyinitiation.
Several recent publications have demonstrated that a
mismatch between expert consensus recommendations
and applied clinical care patterns exists for patients with
pulmonary vascular disease and have shown that this
trend is consistent across various patient populations, in-
cluding community-based, referred, and military veteran
cohorts.
11,15,32 Failure to adhere to consensus recommen-
Table 5. Potential barriers to prescribing preferred therapy in
pulmonary arterial hypertension (PAH)
Potential treatment barrier
Rank order
response
(N ¼ 105),
mean   SD
Social circumstances prevent drug
therapy compliance 2.3   0.1
Comorbid psychological/psychiatric
disease prevents drug therapy compliance 2.8   0.1
Patients’ ﬁnancial circumstances prevent
access to drug therapy 3.2   0.2
Patient refuses drug therapy 3.4   0.1
Drug therapy is not provided by the pharmacy
accessed by the patient or the healthcare
provider 3.7   0.1
Note: Answers are reported on the basis of a rank order
scale (1 ¼ most common barrier to PAH treatment, 5 ¼ least
common barrier to PAH treatment).
Figure 5. Regional differences and the use of a multidisciplin-
ary approach to the management of pulmonary arterial hyper-
tension (PAH) patients. An international cohort of pulmonary
vascular disease experts (N ¼ 105) completed an Internet-based
survey soliciting a response of (dis)agreement to the following
statement: “Key management decisions for PAH patients are
achieved through a consensus decision between a pulmonary
medicine and cardiology expert in pulmonary hypertension.”
Results are presented according to geographic location of prac-
tice. Data are expressed as mean   SD.
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ated with suboptimal rates of diagnosis and treatment. In
one study by Dean ˜o and colleagues,
11 pulmonary hyperten-
sion misdiagnosis rates were as high as 52%, which was
associated with similar rates of inappropriate therapy. Simi-
lar ﬁndings are reported for evaluation completeness for
PAH, in which appropriate screening for root cause of pul-
monary vascular dysfunction, such as connective tissue dis-
ease or human immunodeﬁciency virus, may be as low as
29% in nonreferral populations. Our ﬁndings are in concert
with these earlier observations by suggesting that variability
in care patterns are observed in practice globally even
amongexpert PAH clinicians.
These data identify differences in drug therapy prefer-
ence for PAH patients irrespective of cardiogenic shock
status and by practice location as well as for pharmaco-
therapeutic support in the setting of right ventricular fail-
ure. Although we did not investigate a rationale by which
to account for survey answers, our ﬁndings suggest that
patients’ social circumstances and mental health status may
inﬂuence treatment selection. Our ﬁnding that health in-
surance status may affect diagnostic testing selection in
WHO group 3 pulmonary hypertension is consistent with
observations made in other diseases, indicating that non-
clinical factors inﬂuence care patterns in the absence of
standardized guidelines.
33,34
Disparity was observed for drug class preference in PAH
relative to consensus recommendations: whereas parenteral
PGI2 therapy initiation is supported by a class 1 recommen-
dation in current
35 and recent
12 guidelines for patients with
PAH, cardiogenic shock, and unknown vasoreactivity sta-
tus, several alternative therapies were identiﬁed in our
survey as preferred ﬁrst-line treatment under these clini-
cal conditions. Disparity in opinion was also reported for
the use of calcium channel antagonist therapy in PAH pa-
tients with preserved vasoreactivity despite reproducible
clinical trial data
29,36 and a class 1 recommendation
35 in
support of this drug class as an effective treatment for this
Figure 6. Differences in care patterns for patients with pulmonary vascular disease according to geographic location of clinicians.
An international cohort of pulmonary vascular disease experts completed an Internet-based survey, and results were analyzed
according to US-practice (N = 46) or non-US-practice (N = 57) location. A, Respondents’ (dis)agreement scores are reported in
response to the following statements: “Right heart catheterization is a routine strategy by which to monitor (i.e., follow-up) the
treatment responsiveness of PAH patients to pulmonary vasodilator therapy” (left bar graph) and “It is reasonable to perform
pulmonary vasoreactivity testing as part of the clinical evaluation for patients with suspected chronic lung disease–induced pulmo-
nary hypertension (i.e., World Health Organization [WHO] group 3 pulmonary hypertension)” (right bar graph). RHC: right heart
catheterization; PAH: pulmonary arterial hypertension; VASO-R: vasoreactivity testing. Data are expressed as mean   SD. B,
Percentage of respondents identifying each of 6 potential treatments as the most preferred drug therapy for the ﬁrst-line treatment
of PAH patients with cardiogenic shock. PGI2: prostacyclin analogue; PDE-Vi: phosphodiesterase type 5 inhibitor; ERA: endothelin
receptor antagonist; ETARA: selective endothelin type A receptor antagonist.
448 | Pulmonary hypertension clinical care quality Ryan et al.PAH clinical proﬁle. However, these ﬁndings may be ac-
counted for by published expert recommendations indi-
cating that PDE-Vi, in addition to calcium channel antago-
nist therapy, is an acceptable treatment option under these
clinical conditions.
37 No consensus was observed among
experts for the use of PDE-Vi therapy in WHO group 3 pul-
monary hypertension, which is in concert with varying opin-
ions reported on this issue in the literature.
32,38
There are several limitations to this study beyond factors
intrinsic to survey research that merit discussion when in-
terpreting our ﬁndings. First, our approach was to solicit
survey responses from self-identiﬁed PAH experts belong-
ing to medical organizations with an established commit-
ment to pulmonary vascular disease. The precise survey re-
sponse rate expressed as a fraction of participants relative
to the overall universe of PAH experts, thus, cannot be
calculated, nor were objective criteria for deﬁning PAH
expert used a priori to determine inclusion eligibility in this
study. Taken together, the degree to which our study co-
hort was truly representative of the PAH expert commu-
nity cannot be quantiﬁed beyond PAH-speciﬁc experience,
PAH research involvement, and time commitment in clin-
ical practice devoted to PAH patients (as provided in Ta-
ble 2). Nevertheless, since survey completion alone may
be indicative of participation bias among the study cohort,
interpretation of our data also requires consideration of
this potentially confounding effect.
Second, the survey was distributed internationally in En-
glish. Thus, it is not possible to characterize the potential
confounding effect of language barriers to study participa-
tion and/or answer accuracy. Along these lines, the possi-
bility remains that statement formatting resulted in am-
biguous questions and/or answer selections, which would
undoubtedly introduce a response bias to our results. Addi-
tionally, physicians practicing in the United States repre-
sented the largest geographical group of survey respondents,
a l t h o u g ht h ee f f e c to ft h i so nt h er e s u l t so fa n a l y s e si n v o l v -
ing the entire cohort was not addressed speciﬁcally.
Third, this survey was not intended to identify a ratio-
nale by which to account for respondents’ survey question
answers. Therefore, it is conceivable that inaccessibility
to resources (or clinical experiences) necessary to inter-
pret question(s) accurately contributed to answer selection,
ratherthanclinicalacumenalone.
Conclusions
Despite the availability of a contemporary expert consen-
sus statements, there is disparity in opinion regarding
the clinical approach to PAH among experts in the ﬁeld.
Speciﬁcally, divergence from evidence-based recommen-
dations was reported in this survey study for diagnostic
strategies and application of drug therapy for patients,
which was observed across different hypothetical clinical
scenarios. These data illustrate the need for standardized
and validated clinical guidelines in the ﬁeld of pulmonary
vascular disease, which is anticipated to improve outcome
in patients afﬂicted with PAH and other diseases of simi-
lar pathophysiology.
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